These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24925289)

  • 1. Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure.
    Gruson D; Mancini M; Ahn SA; Rousseau MF
    Clin Biochem; 2014 Aug; 47(12):1006-9. PubMed ID: 24925289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.
    Gruson D; Mancini M; Ahn SA; Rousseau MF
    Clin Chim Acta; 2014 Feb; 429():189-93. PubMed ID: 24365381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function largely influences Galectin-3 prognostic value in heart failure.
    Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
    Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
    Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
    Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
    Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
    J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
    Meijers WC; van der Velde AR; de Boer RA
    Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients.
    Feola M; Testa M; Leto L; Cardone M; Sola M; Rosso GL
    Medicine (Baltimore); 2016 Jun; 95(26):e4014. PubMed ID: 27368017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic profile provides prognostic value better than galectin-3 in patients with heart failure.
    Wang CH; Cheng ML; Liu MH; Kuo LT; Shiao MS
    J Cardiol; 2017 Jul; 70(1):92-98. PubMed ID: 28318874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
    Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
    PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments.
    Gaze DC; Prante C; Dreier J; Knabbe C; Collet C; Launay JM; Franekova J; Jabor A; Lennartz L; Shih J; del Rey JM; Zaninotto M; Plebani M; Collinson PO
    Clin Chem Lab Med; 2014 Jun; 52(6):919-26. PubMed ID: 24445238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance characteristics of the ARCHITECT Galectin-3 assay.
    La'ulu SL; Apple FS; Murakami MM; Ler R; Roberts WL; Straseski JA
    Clin Biochem; 2013 Jan; 46(1-2):119-22. PubMed ID: 23010446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
    Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
    Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices.
    Erkilet G; Özpeker C; Böthig D; Kramer F; Röfe D; Bohms B; Morshuis M; Gummert J; Milting H
    J Heart Lung Transplant; 2013 Feb; 32(2):221-30. PubMed ID: 23352394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma galectin 3 and heart failure risk in the Physicians' Health Study.
    Djoussé L; Matsumoto C; Petrone A; Weir NL; Tsai MY; Gaziano JM
    Eur J Heart Fail; 2014 Mar; 16(3):350-4. PubMed ID: 24464746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
    Leone M; Iacoviello M
    Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
    Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
    Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
    Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults.
    Schindler EI; Szymanski JJ; Hock KG; Geltman EM; Scott MG
    Clin Chem; 2016 Feb; 62(2):360-6. PubMed ID: 26546635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.
    Asleh R; Enriquez-Sarano M; Jaffe AS; Manemann SM; Weston SA; Jiang R; Roger VL
    J Am Coll Cardiol; 2019 May; 73(18):2286-2295. PubMed ID: 31072572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.